These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 24976475)

  • 1. Atrial fibrillation and quality of life related to disease and treatment: focus on anticoagulation.
    Ynsaurriaga FA; Peinado RP; Ormaetxe Merodio JM
    Future Cardiol; 2014 May; 10(3):381-93. PubMed ID: 24976475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.
    Lip GY; Laroche C; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Ioachim PM; Tica O; Boriani G; Cimaglia P; Diemberger I; Hellum CF; Mortensen B; Maggioni AP
    Am J Med; 2014 Jun; 127(6):519-29.e1. PubMed ID: 24486284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stroke prevention in patients with atrial fibrillation: focus on new oral anticoagulants.
    Toth PP
    Postgrad Med; 2013 May; 125(3):155-61. PubMed ID: 23748516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation.
    Garcia DA
    Thromb Res; 2012 Jan; 129(1):9-16. PubMed ID: 22018997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
    J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.
    Aguilar MI; Kuo RS; Freeman WD
    Neurol Clin; 2013 Aug; 31(3):659-75. PubMed ID: 23896498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE.
    Hess CN; Al-Khatib SM; Granger CB; Lopes R
    Expert Rev Cardiovasc Ther; 2013 Sep; 11(9):1105-14. PubMed ID: 23992517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel anticoagulants for atrial fibrillation: a critical appraisal.
    Tzeis S; Andrikopoulos G
    Angiology; 2012 Apr; 63(3):164-70. PubMed ID: 22007032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled trials of new oral anticoagulants for stroke prevention in atrial fibrillation.
    Liew A; Eikelboom JW; O'Donnell M
    Curr Opin Cardiol; 2012 Jul; 27(4):331-9. PubMed ID: 22573171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel oral anticoagulants in secondary prevention of stroke.
    Diener HC; Easton JD; Hankey GJ; Hart RG
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Striking a balance between the risks and benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical updates and remaining controversies.
    Garwood CL; Hwang JM; Moser LR
    Pharmacotherapy; 2011 Dec; 31(12):1208-20. PubMed ID: 22122182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ximelagatran for stroke prevention in atrial fibrillation.
    Boos CJ; Lip GY
    Expert Rev Cardiovasc Ther; 2005 Jul; 3(4):551-63. PubMed ID: 16076267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
    Paikin JS; Haroun MJ; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):279-86. PubMed ID: 21438804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalizing oral anticoagulant treatment in patients with atrial fibrillation.
    Capranzano P; Miccichè E; D'Urso L; Privitera F; Tamburino C
    Expert Rev Cardiovasc Ther; 2013 Aug; 11(8):959-73. PubMed ID: 23957907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.